The Imaging Core will perform all MR and bioluminescence imaging studies on mouse tumor models for Projects 1 and 2. In addition, the Imaging Core is responsible for all preclinical and clinical data archiving, post-processing and analysis. Core personnel will provide services including: (a) define and implement data acquisition/imaging sequences; (b) assist with animal preparation for imaging; (c) perform all data collection on the 9.4 Tesla MRI, 7 Tesla MRI and Caliper bioluminescence imaging systems; (d) preliminary data processing/image reconstruction and quantitative analysis including PRM analysis for both preclinical (Projects 1 and 2) and clinical imaging data (Project #3) and outcomes data; (e) secure archival of raw data and network transfer of reconstructed data from off-site facilities; (f) scheduling of imaging experiments; and (g) provide support to Program Investigators in technical design and implementation of imaging experiments. These services are designed, in part, after a clinical MRI service model since continual, high-volume animal scanning is essential for the success of each project Specific animal MRI protocols will vary with each project, but will primarily include serial studies using: standard T2-weighted; Tl-weighted dynamic contrast enhanced; multislice quantitative water diffusion mapping and dynamic contrast enhancing permeability mapping. The Core will also facilitate the identification of the spatial coordinates needed for biopsy of mouse gliomas using stereotaxic procedures and facilite this activity. The Core will also assist with transfer of MR data to Imbio, LLC for offsite analysis of diffusion and perfusion MRI data sets acquired at multiple sites. Dr. Galban will serve as Core B Director. Dr. Galban has extensive experience in small animal imaging research as well as digital image processing and analysis of clinical MRI data. A Co-investigator and staff will assist Dr. Galban with adapting image processing algorithm's and associated analysis software to ensure the needs of this programmatic research effort are fully met.
Overall, this research effort will provide the imaging data and analysis for evaluating improved approaches including the use of molecularly targeted therapies for the treatment of malignant brain tumors. Additionally, imaging biomarkers for early assessment of treatment response and recurrence will be identified and validated which will lead to individualization of patient care.
| Smith, Andrew; Pawar, Mercy; Van Dort, Marcian E et al. (2018) Ocular Toxicity Profile of ST-162 and ST-168 as Novel Bifunctional MEK/PI3K Inhibitors. J Ocul Pharmacol Ther 34:477-485 |
| Akgül, Seçkin; Li, Yinghua; Zheng, Siyuan et al. (2018) Opposing Tumor-Promoting and -Suppressive Functions of Rictor/mTORC2 Signaling in Adult Glioma and Pediatric SHH Medulloblastoma. Cell Rep 24:463-478.e5 |
| Pal, Anupama; Rehemtulla, Alnawaz (2018) Imaging Proteolytic Activities in Mouse Models of Cancer. Methods Mol Biol 1731:247-260 |
| Durmo, Faris; Lätt, Jimmy; Rydelius, Anna et al. (2018) Brain Tumor Characterization Using Multibiometric Evaluation of MRI. Tomography 4:14-25 |
| Van Dort, Marcian E; Galbán, Stefanie; Nino, Charles A et al. (2017) Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168). ACS Med Chem Lett 8:808-813 |
| Galbán, Stefanie; Al-Holou, Wajd N; Wang, Hanxiao et al. (2017) MRI-Guided Stereotactic Biopsy of Murine GBM for Spatiotemporal Molecular Genomic Assessment. Tomography 3:9-15 |
| Barthel, Floris P; Wei, Wei; Tang, Ming et al. (2017) Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet 49:349-357 |
| Hu, Xin; Martinez-Ledesma, Emmanuel; Zheng, Siyuan et al. (2017) Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. Neuro Oncol 19:786-795 |
| Nyati, Shyam; Young, Grant; Ross, Brian Dale et al. (2017) Quantitative and Dynamic Imaging of ATM Kinase Activity. Methods Mol Biol 1596:131-145 |
| Galbán, Stefanie; Apfelbaum, April A; Espinoza, Carlos et al. (2017) A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis. Mol Cancer Ther 16:2340-2350 |
Showing the most recent 10 out of 170 publications
